Nurix Therapeutics outlines 2023 clinical milestones for BTK degraders and CBL-B inhibitor at JPM Conference

Nurix Therapeutics, Inc.

NX-2127 BTK degrader: clinical update and regulatory strategy in H2 2023.
NX-5948 BTK degrader: initial Phase 1a data and dose for expansion in H2 2023.
NX-1607 CBL-B inhibitor: Phase 1a data and dose for expansion in H2 2023.
Cash, equivalents and marketable securities of $413.6M as of Aug 2022; runway into Q4 2024.
Raised $115M in 2022; expects to select new development candidate in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.